ReviewInternational journal of molecular sciences2023
Psoriatic Arthritis: Pathogenesis and Targeted Therapies.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 5 syntheses or guidelines pooled it, 154 citations in OpenAlex.
- Sex Hormones in Psoriatic Disease: A Systematic Review.American journal of clinical dermatology · 2026Pooled it
- IL-17 ligand-targeting inhibitors in psoriatic arthritis: a focused systematic review and network meta-analysis of efficacy, safety, and certainty of evidence.Frontiers in immunology · 2026Pooled it
- Nutrition and diet in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: a systematic review.Frontiers in medicine · 2025Pooled it
- Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: An Updated Systematic Literature Review.PharmacoEconomics · 2024Pooled it
- Efficacy and safety of tofacitinib for chronic plaque psoriasis and psoriatic arthritis: a systematic review and meta-analysis of randomized controlled trials.Clinical rheumatology · 2024Pooled it
- Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase 3 Study.Arthritis & rheumatology (Hoboken, N.J.) · 2025Trial
- The expanding role of biocompatible hydrogels in plant-derived exosome-like nanovesicles for skin diseases: prospects and challenges.Annals of medicine · 2026Review
- CRP at diagnosis in psoriatic arthritis: what it means and associations with long-term outcomes.Rheumatology (Oxford, England) · 2026Article
- Named Radiological Signs in Psoriatic Arthritis: A Pictorial Overview.Indian dermatology online journal · 2026Article
- The IL-23/-17 Axis in PsA: What Have We Learned in the Last 20 Years?Mediterranean journal of rheumatology · 2026Article
- Multi-omics Mendelian randomization identified adaptive immune response-related drug targets in psoriatic arthritis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Associations of cardiovascular health and genetic susceptibility with incident psoriatic arthritis: findings from two cohort studies.Clinical rheumatology · 2026Article
- Systemic Immune-Inflammation Index (SII) as a Predictive Biomarker of Therapeutic Response in Psoriasis: A Retrospective Comparative Analysis of Anti-TNF, Anti-IL-17, and Anti-IL-23 Agents.Journal of personalized medicine · 2026Article
- Pro-Inflammatory Synergy Between IL-17, IL-1 and Hyperuricemia in Psoriatic Arthritis: Clinical Implications of a Pilot Study.Diseases (Basel, Switzerland) · 2026Article
- Psoriatic Arthritis: Therapeutic Advances and Novel Treatment Strategies-A Scoping Review.Life (Basel, Switzerland) · 2026Review
- Nanotechnology advances for psoriasis treatment and future prospects.Discover nano · 2026Review
- Using causal machine learning and real world data to improve dose response decision making for secukinumab in psoriatic arthritis.Scientific reports · 2026Article
- Excess cardiovascular morbidity in psoriatic arthritis and cardioprotective effects of biologic dmards: a propensity-matched analysis.Scientific reports · 2026Article
- Inflammatory protein profiling in immune cells identifies molecular signatures for enhanced diagnostic precision in psoriatic arthritis.Molecular biomedicine · 2026Article
- Integrative bioinformatics-machine learning-experimental validation identifies shared immunomodulatory targets in psoriasis and psoriatic arthritis and deciphers allicin's therapeutic mechanism.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriatic arthritis (PsA), a heterogeneous chronic inflammatory immune-mediated disease characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis, and dactylitis), generally occurs in patients with psoriasis. PsA is also associated with uveitis and inflammatory bowel disease (Crohn's disease and ulcerative colitis). To capture these manifestations as well as the associated comorbidities, and to recognize their underlining common pathogenesis, the name of psoriatic disease was coined. The pathogenesis of PsA is complex and multifaceted, with an interplay of genetic predisposition, triggering environmental factors, and activation of the innate and adaptive immune system, although autoinflammation has also been implicated. Research has identified several immune-inflammatory pathways defined by cytokines (IL-23/IL-17, TNF), leading to the development of efficacious therapeutic targets. However, heterogeneous responses to these drugs occur in different patients and in the different tissues involved, resulting in a challenge to the global management of the disease. Therefore, more translational research is necessary in order to identify new targets and improve current disease outcomes. Hopefully, this may become a reality through the integration of different omics technologies that allow better understanding of the relevant cellular and molecular players of the different tissues and manifestations of the disease. In this narrative review, we aim to provide an updated overview of the pathophysiology, including the latest findings from multiomics studies, and to describe current targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.